Atezolizumab Suppliers & Bulk Manufacturers
Available Forms: Intravenous infusion
Available Strengths: 1200 mg/20 mL
Reference Brands: Tecentriq® (EU & US)
Category:
Oncology Cancer Care
Atezolizumab (Tecentriq®) is a PD-L1 checkpoint inhibitor used in urothelial carcinoma, NSCLC, and triple-negative breast cancer. Available as sterile IV infusion vials (1200 mg/20 mL), manufactured under EU-GMP and USFDA standards. Ideal for B2B supply, hospital tenders, and licensing.
Atezolizumab is available in Intravenous infusion
and strengths such as 1200 mg/20 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Atezolizumab is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Atezolizumab can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Atezolizumab (Tecentriq®) is a PD-L1 immune checkpoint inhibitor indicated for urothelial carcinoma, NSCLC, and triple-negative breast cancer. Provided as sterile intravenous infusion vials (1200 mg/20 mL), Atezolizumab is produced under EU-GMP and USFDA standards. Offered for B2B supply, contract manufacturing, and licensing, it supports hospital tenders and oncology distributors with full regulatory documentation. This monoclonal antibody restores anti-tumor immunity by blocking PD-L1, making it a vital immuno-oncology therapy in US and European cancer treatment portfolios.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing